Author(s): Vilas S Jadhav *and Dr. Deenanath Jhade
Since malaria is an illness that may rapidly progress to severe disease and even death, early diagnosis and prompt treatment of acute malaria episodes is an important strategy to reduce morbidity and mortality. The first and most important role of diagnosis is in patient management. Currently there is several medicines are available in the market and containing individual drugs. The major challenge in the malaria to provide or prescribe required dose to cure it in due course of time. The major part covered here to develop the combination therapy required to treat malaria to avoid over or low dose during the treatment. The main drug used in the treatment is Chloroquine and Azithromycin to cure in shortest period of time. In present invention, the development of fix dose combination of Azithromycin and Chloroquine required treating malaria as most effective treatment. Based on overall literature search and studies, it was found that Azithromycin 250mg and Chloroquine 200mg are most suitable strength and combination to be used to trate the malaria. The objective of the present study was to formulate suspension of Azithromycin dihydrate (AZT) and Chloroquine (CQ) as fix dose combination useful to treat Malaria. Individually, Azithromycin and Chloroquine tablets are available in the market to treat malaria. However, there is no fix treatment dose are given during treatment. The present study is to develop safest and effective fix dose combination of Azithromycin and Chloroquine tablets. Key words: Azithromycin, Chloroquine, Quality By Design, Malaria, Fix dose combination.
Journal of Harmonized Research in Pharmacy received 24 citations as per google scholar report